How Ampicillin-Sulbactam Treats Bacterial Infections

Ampicillin-sulbactam is a combination antibiotic that pairs a well-known penicillin (ampicillin) with a compound (sulbactam) whose main job is to protect it from being destroyed by bacterial enzymes. The combination has been in clinical use since the 1980s and remains a workhorse for mixed infections involving both aerobic and anaerobic bacteria, from intra-abdominal infections to bite wounds to aspiration pneumonia. What makes it interesting pharmacologically is that sulbactam is not just a passive shield for ampicillin; against certain bacteria, it has antibacterial activity of its own.

How the Combination Works

Ampicillin kills bacteria by binding to penicillin-binding proteins (PBPs), enzymes that bacteria need to build and maintain their cell walls. Without functional PBPs, bacteria cannot divide properly and eventually burst. The problem is that many bacteria produce enzymes called beta-lactamases, which chew up ampicillin’s chemical ring structure before it can reach its targets. Sulbactam is a beta-lactamase inhibitor: it binds irreversibly to certain beta-lactamases, acting as a decoy that sacrifices itself so ampicillin can do its work. Structural studies have shown that sulbactam forms a stable bond with class A beta-lactamases, the most common family of these enzymes in clinically relevant bacteria.¹

Sulbactam does more than just protect ampicillin, though. Against Acinetobacter baumannii, a notoriously drug-resistant hospital-acquired pathogen, sulbactam has direct killing power. Research has demonstrated that sulbactam inhibits PBP1 and PBP3 in A. baumannii, meaning it disrupts cell wall construction on its own in this organism.² This intrinsic activity is why sulbactam-containing regimens have historically been among the few options for treating Acinetobacter infections, and why newer drug development has continued to build on sulbactam rather than abandon it.

What Infections It Treats

Ampicillin-sulbactam covers a broad range of bacteria, including many gram-positive organisms (like streptococci and some staphylococci), gram-negative organisms (like E. coli, Klebsiella, and Haemophilus influenzae), and anaerobes.³ That breadth, especially the anaerobic coverage, makes it useful wherever infections involve a messy mix of organisms.

The anaerobic activity is particularly strong against Bacteroides fragilis, one of the most common culprits in abdominal infections. Early in vitro work showed that the ampicillin-sulbactam combination inhibited about 98 to 99% of anaerobic strains tested, and that the improvement over ampicillin alone was most dramatic for B. fragilis.⁴ For organisms like Fusobacterium and most gram-positive anaerobes, which are already sensitive to ampicillin on its own, adding sulbactam did not make much difference.

The main clinical niches for ampicillin-sulbactam include:

Intra-abdominal infections: A randomized trial comparing it with cefoxitin (a second-generation cephalosporin) found clinical success in about 86% of patients on ampicillin-sulbactam versus 78% on cefoxitin, with comparable safety profiles.⁵ Another early trial found it was a useful alternative to the classic gentamicin-plus-clindamycin regimen, with similar cure rates and lower toxicity concerns.⁶
Aspiration pneumonia and lung abscess: Aspiration events introduce mouth flora into the lungs, creating mixed aerobic-anaerobic infections. A multicenter trial found that ampicillin-sulbactam achieved a clinical response of about 73% at the end of therapy and was equally effective as clindamycin-based regimens.⁷ A separate comparison with moxifloxacin found identical overall response rates of about 67% for both drugs, with good tolerability even during long treatment courses.⁸
Skin and soft tissue infections: The Infectious Diseases Society of America guidelines list ampicillin-sulbactam among the recommended broad-spectrum options (alongside piperacillin-tazobactam and carbapenems) for severe polymicrobial soft tissue infections, including necrotizing infections when the causative organism is not yet identified.⁹
Diabetic foot infections: A randomized trial comparing ampicillin-sulbactam with piperacillin-tazobactam for infected diabetic foot ulcers found statistically equivalent clinical cure or improvement rates: about 83% for ampicillin-sulbactam versus 81% for piperacillin-tazobactam.¹⁰

Where It Falls Short

Ampicillin-sulbactam is not a good fit for every kind of infection. It does not cover methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, or most extended-spectrum beta-lactamase (ESBL)-producing gram-negative organisms. These gaps mean it is generally not a first-line choice for hospital-acquired infections where resistant gram-negative bacteria are a concern, or for any infection where MRSA is likely.

Even within its target infections, the drug is not universally dominant. A randomized trial in community-acquired complicated intra-abdominal infections found that ampicillin-sulbactam had a higher clinical failure rate for lower gastrointestinal tract infections compared with moxifloxacin (about 20% versus 4%), and multivariable analysis identified ampicillin-sulbactam therapy as an independent risk factor for treatment failure in that trial population.¹¹ That finding was from a single study, and the overall failure rates between the two drugs were not statistically different (about 16% versus 12%), but it suggests that for infections originating below the stomach, other agents may sometimes perform better.

A stewardship evaluation at a single hospital found that when clinicians chose ampicillin-sulbactam on their own without restrictions, the drug was appropriately prescribed in only about half of empiric orders. The most common misapplications were intra-abdominal infections and urinary tract infections, where local resistance patterns or the wrong spectrum made other drugs a better fit.¹² The drug tends to be ordered reflexively for conditions where it once worked well but local resistance has since shifted, a common pattern with older antibiotics.

How Bacteria Resist It

Resistance to ampicillin-sulbactam can develop through several routes, reflecting the same multilayered defense mechanisms bacteria use against beta-lactam antibiotics more broadly: increased beta-lactamase production, changes to the drug’s target proteins, reduced drug entry through altered outer membrane channels, and active drug pumping out of the cell.¹³

In E. coli, the most common culprit is overproduction of the TEM-1 beta-lactamase. Rather than acquiring a new type of enzyme that sulbactam cannot inhibit, these bacteria simply crank out so much of the ordinary TEM-1 enzyme that sulbactam gets overwhelmed. A study of 50 ampicillin-sulbactam-resistant E. coli bloodstream isolates found that this high-level expression of TEM-1 was the predominant resistance mechanism, and that the bacteria did not appear clonally related, suggesting this resistance arises independently in different strains rather than spreading from a single source.¹⁴

In A. baumannii, the picture is different and arguably more worrying. Two key mechanisms stand out in large surveillance studies from China: the presence of blaTEM-1D (a beta-lactamase gene) and ISAba1-ampC (a genetic element that cranks up production of an intrinsic beta-lactamase). Among over 2,000 A. baumannii isolates, the sulbactam resistance rate was about 40%, and sulbactam-nonsusceptible strains overwhelmingly carried these genetic markers while susceptible strains did not.¹⁵ Additionally, expression of an efflux pump gene called adeB has been associated with resistance to both ampicillin-sulbactam and ciprofloxacin in A. baumannii, meaning the same pump that expels one drug can also expel the other.¹⁶

How the Body Handles the Drug

Both ampicillin and sulbactam behave similarly in the body, which is pharmacologically convenient. After intravenous administration, both drugs have half-lives of roughly one hour and are primarily cleared by the kidneys through active tubular secretion (not just passive filtration).¹⁷ Both drugs distribute well into extracellular fluids, which matters because infections live in those tissue spaces, not just in the bloodstream.

The matched pharmacokinetic profiles are not a coincidence. Both drugs are small beta-lactam molecules with similar charges and sizes, so they move through the body at about the same rate. This means that wherever ampicillin goes, sulbactam follows at a predictable ratio, and clinicians do not have to worry about one drug outpacing the other. In patients with impaired kidneys, both drugs slow down in parallel: total body clearance decreases, but the ratio between them stays constant, so dose adjustments can be made without changing the 2:1 ampicillin-to-sulbactam ratio.¹⁸

The standard intravenous formulation is given every six to eight hours because of those short half-lives. Once reconstituted in normal saline, the ampicillin component remains stable for about 32 hours at room temperature and about 68 hours refrigerated, which has practical implications for how the drug is prepared and stored in hospitals.¹⁹

The Oral Form and How It Differs

Ampicillin and sulbactam are both poorly absorbed from the gut when taken separately by mouth. The oral version gets around this problem by linking the two molecules together chemically into a single compound called sultamicillin. Once swallowed, sultamicillin is broken down during absorption through the gut wall, releasing equal amounts of sulbactam and ampicillin into the bloodstream.²⁰ The result is far better absorption than either drug achieves alone. In human volunteers, the bioavailability of both ampicillin and sulbactam from a single oral dose of sultamicillin exceeded 80%.²¹

Sultamicillin is available in many countries outside the United States and is used for milder infections where intravenous therapy is not necessary, or as step-down therapy after a course of IV ampicillin-sulbactam. The prodrug design is elegant: it solves a pharmacokinetic problem without requiring any change to the drug’s mechanism of action. In the U.S., sultamicillin is not FDA-approved, so clinicians who want to switch from IV ampicillin-sulbactam to an oral antibiotic typically pivot to amoxicillin-clavulanate (a related beta-lactam/inhibitor combination) rather than sultamicillin.

Pregnancy and Pediatric Use

Pregnancy changes the way the body handles many drugs, and ampicillin-sulbactam is no exception. In pregnant women, ampicillin is cleared faster and reaches lower peak blood levels compared with non-pregnant women, due to the increased blood volume and kidney function that come with pregnancy.²² Sulbactam showed similar trends, though the differences were not as statistically pronounced. The clinical significance is that pregnant patients may need careful attention to dosing, especially for serious infections, to ensure adequate drug levels are maintained.

In children, the pharmacokinetics of both drugs are comparable to those in adults when adjusted for body weight. A study across three pediatric age groups found that ampicillin and sulbactam reached similar peak concentrations and had similar clearance rates regardless of age, and the combination was well tolerated.²³ Gender did not affect the pharmacokinetics either. This consistency across age groups makes dosing relatively straightforward: weight-based calculations work, and no special adjustments beyond that are needed for children.

Sulbactam-Durlobactam and the Future of Sulbactam-Based Therapy

The rise of carbapenem-resistant Acinetobacter baumannii (CRAB) has created an urgent need for new antibiotics. Carbapenems were long considered the last line of reliable therapy for multidrug-resistant gram-negative infections, and once Acinetobacter developed resistance to those, clinicians were left with few options, most of them toxic. Colistin, a decades-old drug with serious kidney toxicity, became the default choice largely because nothing better was available.

Sulbactam’s intrinsic activity against Acinetobacter made it a natural starting point for developing something better. The result is sulbactam-durlobactam, a next-generation combination that pairs sulbactam with a new beta-lactamase inhibitor (durlobactam) that protects sulbactam from the resistance enzymes that Acinetobacter has acquired over the years. In a phase 3 randomized trial (the ATTACK trial), sulbactam-durlobactam was compared head-to-head with colistin in patients with serious CRAB infections, with both groups receiving imipenem-cilastatin as background therapy.²⁴ The drug demonstrated non-inferiority to colistin and has since been approved in the U.S. for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter strains.²⁵

The development arc from ampicillin-sulbactam to sulbactam-durlobactam illustrates something unusual in antibiotic history. In most resistance stories, the old drug is abandoned and something structurally unrelated takes its place. Here, the active component against the problem organism was sulbactam all along, and the fix was not to replace it but to give it a better bodyguard. Whether that approach has legs beyond Acinetobacter remains to be seen, but for one of the most dangerous hospital-acquired pathogens in the world, it has already changed clinical practice.